Taken together, our results suggest that both CD4+ and CD8+ subtypes of MET-CAR-T cells can be responsible for the anti-tumor efficacy, and that CD4+ MET-CAR-T cells may elicit more robust effector T cell functions when applied to clinical settings. Here, MET is linked to neoplasm.